A number of research firms have changed their ratings and price targets for AveXis (NASDAQ: AVXS):

  • 10/12/2017 – AveXis had its price target raised by analysts at Jefferies Group LLC to $118.00. They now have a “buy” rating on the stock.
  • 10/12/2017 – AveXis had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $130.00 price target on the stock, up previously from $123.00.
  • 10/6/2017 – AveXis had its “buy” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $130.00 price target on the stock.
  • 10/3/2017 – AveXis had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $122.00 price target on the stock, up previously from $95.00.
  • 10/2/2017 – AveXis had its price target raised by analysts at Citigroup Inc. from $100.00 to $116.00. They now have a “buy” rating on the stock.
  • 9/30/2017 – AveXis had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $123.00 price target on the stock.
  • 9/29/2017 – AveXis had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company.
  • 9/14/2017 – AveXis is now covered by analysts at Royal Bank Of Canada. They set a “sector perform” rating and a $92.00 price target on the stock.
  • 9/7/2017 – AveXis was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company’s product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. “
  • 9/6/2017 – AveXis is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $124.00 price target on the stock.
  • 9/5/2017 – AveXis had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $134.00 price target on the stock, up previously from $89.00.
  • 8/29/2017 – AveXis is now covered by analysts at Instinet. They set a “reduce” rating and a $52.00 price target on the stock.
  • 8/28/2017 – AveXis is now covered by analysts at Nomura. They set a “reduce” rating and a $52.00 price target on the stock.

Shares of AveXis, Inc. (NASDAQ:AVXS) traded up 0.11% during trading on Monday, hitting $100.17. The stock had a trading volume of 307,212 shares. AveXis, Inc. has a 12 month low of $44.68 and a 12 month high of $106.00. The company’s 50 day moving average price is $96.02 and its 200 day moving average price is $84.59. The stock’s market cap is $3.20 billion.

AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($1.10). During the same quarter in the previous year, the firm posted ($0.68) earnings per share. Equities research analysts expect that AveXis, Inc. will post ($6.22) earnings per share for the current fiscal year.

In other AveXis news, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $101.46, for a total transaction of $1,521,900.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $93.25, for a total value of $165,985.00. Following the sale, the vice president now owns 1,780 shares in the company, valued at approximately $165,985. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,340 shares of company stock worth $2,023,896. 18.60% of the stock is owned by company insiders.

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.